Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response

Journal of Viral Hepatitis, 05/14/2012

A SVR to anti–HCV therapy is thus associated with a markedly reduced risk of severe transaminitis during antiretroviral therapy. Treatment of HCV infection should therefore be a priority in HIV–coinfected patients. Stavudine is associated with an increased risk of severe transaminitis.

Print Article Summary Cat 2 CME Report